FN3 Protein Scaffold Consensus Design for Therapeutic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic proteins, such as monoclonal antibodies, face challenges in terms of high production costs, immunogenicity, and the need for cold chain storage, while alternative scaffold proteins like the FN3 domain offer advantages like small size, stability, and ease of expression in prokaryotic hosts but require improved methods for binding specificity and affinity.
Innovation Solution
Development of a protein scaffold based on a consensus sequence of multiple FN3 domains from human Tenascin, which can be designed to bind various molecules, including cellular targets, and can incorporate additional moieties like the Fc region of an antibody or albumin binding domains to enhance stability and half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used as therapeutic proteins, then high affinity and specificity for target molecules are achieved, but production costs increase and immunogenicity occurs
Solution Approach 1:
The patent creates simplified copies of antibody binding domains by using consensus sequences derived from multiple FN3 domain variants. These consensus sequences capture the essential binding features while removing variable, non-essential elements, resulting in cheaper-to-produce proteins that maintain target binding capability
Solution Approach 2:
The patent extracts only the essential binding-functional elements from complex monoclonal antibodies by isolating and optimizing the FN3 domain consensus sequence. This extraction removes unnecessary complexity (constant regions, Fc portions, etc.) while retaining the core antigen-binding capability, reducing production costs
2Reliability
If monoclonal antibodies are used as therapeutic proteins, then high affinity and specificity for target molecules are achieved, but immunogenicity occurs
Solution Approach 1:
The patent employs prokaryotic expression systems to produce short-lived, non-human proteins that serve their therapeutic function without integrating into human immune memory. The consensus sequence approach creates simplified proteins that are less likely to trigger immune responses while maintaining binding function
Solution Approach 2:
By using consensus sequences from non-human sources (bacterial, viral, plant FN3 domains) rather than human antibody sequences, the patent creates binding proteins that are structurally similar in function but immunologically distinct, reducing immunogenicity
3Reliability
If monoclonal antibodies are used as therapeutic proteins, then high affinity and specificity for target molecules are achieved, but cold chain storage is required
Solution Approach 1:
The patent introduces disulfide bridges at strategically positioned cysteine residues within the FN3 domain consensus sequence. These covalent crosslinks stabilize the protein's three-dimensional structure, increasing thermal resistance and allowing storage at higher temperatures without cold chain requirements
4Ease of manufacture
If alternative scaffold proteins like FN3 domain are used, then small size, stability, and ease of expression in prokaryotic hosts are achieved, but binding specificity and affinity require improvement
Solution Approach 1:
The patent applies local quality optimization by focusing mutagenesis and consensus sequence construction specifically on the loop regions (L1, L2, L3, L4) of the FN3 domain that directly contact the target. The core beta-sandwich structure remains conserved for stability, while local loop sequences are diversified to maximize binding affinity and specificity
Data Source
AI summary
A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.